R&D News | pharmaphorum

News

Heather Turner, LB Pharma's chief executive.

After a long biotech IPO lull, LB Pharma chances its arm

After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.

News

Novartis nabs cardio drug with $1.4bn Tourmaline buy

Novartis has bulked up in cardiology with a $1.4bn takeover of Tourmaline Bio and its drug for atherosclerotic cardiovascular disease (ASCVD).

News

Mixed data from lung cancer trials on show at WCLC

Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.

News

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases.

News

Servier bets $450m on Fragile X syndrome drug

Servier has pushed its emerging neurology pipeline into the clinical trials stage by licensing a drug for Fragile X syndrome from the UK's Kaerus.

News

FDA releases previously unseen CRLs in transparency push

The FDA's earlier decision to publish complete response letters was largely a repackaging of existing information, but now it has gone much further.

After a long biotech IPO lull, LB Pharma chances its arm

Novartis nabs cardio drug with $1.4bn Tourmaline buy

Mixed data from lung cancer trials on show at WCLC

NRG raises £50m to start trials of Parkinson's, ALS drug

Servier bets $450m on Fragile X syndrome drug

FDA releases previously unseen CRLs in transparency push

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks